Locoregional Treatment of Glioblastoma With Targeted α Therapy

医学 多塔 总体生存率 内科学 胶质母细胞瘤 不利影响 肿瘤科 核医学 癌症研究 体内 生物 生物技术
作者
Leszek Królicki,Jolanta Kunikowska,Frank Bruchertseifer,Radosław Kuliński,Dariusz Pawlak,Henryk Koziara,Rafał Rola,Alfred Morgenstern,Adrian Merlo
出处
期刊:Clinical Nuclear Medicine [Lippincott Williams & Wilkins]
卷期号:48 (5): 387-392 被引量:10
标识
DOI:10.1097/rlu.0000000000004608
摘要

Glioblastoma (GB) is the most malignant primary brain tumor. Therefore, introduction of new treatment options is critically important. The aim of this study was to assess local treatment with α emitters [ 213 Bi]Bi-DOTA-substance P (SP) and [ 225 Ac]Ac-DOTA-SP.Treatment was performed as salvage therapy in patients with recurrent primary and secondary GB. [ 213 Bi]Bi-DOTA-SP with injected activity 1.85 GBq per cycle was used in 20 primary (48.2 ± 11.8 years old) and in 9 secondary (38.8 ± 10.8 years old) GB patients and [ 225 Ac]Ac-DOTA-SP in 15 primary (45.1 ± 9.9 years old) and in 6 secondary (37.8 ± 6.4 years old) GB patients with a dose escalation scheme (10, 20, and 30 MBq).Local treatment with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP was well tolerated with only few adverse effects. There was no statistically significant difference between [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP groups in survival parameters. For primary GB, survival parameters of patients treated with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP were as follows(in months): progression-free survival time, 2.7 versus 2.4; OS-d (overall survival from time of diagnosis to death from any cause), 23.6 versus 21.0; OS-t (overall survival from the start of treatment to death from any cause), 7.5 versus 5.0; and OS-r (overall survival from recurrence in primary tumors to death from any cause), 10.9 versus 12.0. Survival parameters of secondary GB patients treated with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP were as follows (in months): progression-free survival time, 5.8 versus 2.4; OS-d, 52.3 versus 65.0; OS-t, 16.4 versus 16.0; and OS-c (overall survival from conversion into secondary GB multiforme to death from any cause), 18.4 versus 36.0.The similarity results of 213 Bi or 225 Ac may suggest that the local treatment of brain tumors can be greatly simplified. The experience to date shows that local radioisotope treatment of brain tumors requires further dosimetry studies, taking into account the complexity of biological processes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
nojego完成签到,获得积分10
刚刚
量子星尘发布了新的文献求助10
3秒前
小小咸鱼完成签到 ,获得积分10
6秒前
11秒前
研友_nqv5WZ完成签到 ,获得积分10
15秒前
量子星尘发布了新的文献求助10
19秒前
19秒前
zhangchunjie发布了新的文献求助20
21秒前
小呵点完成签到 ,获得积分10
22秒前
巴啦啦小魔仙完成签到 ,获得积分10
23秒前
lemontree发布了新的文献求助10
24秒前
陈辉完成签到,获得积分10
28秒前
量子星尘发布了新的文献求助10
28秒前
在水一方应助Capital采纳,获得10
34秒前
GingerF应助黑喂狗狗采纳,获得50
35秒前
海英完成签到,获得积分10
35秒前
科研通AI5应助lemontree采纳,获得10
37秒前
量子星尘发布了新的文献求助10
41秒前
41秒前
learningu完成签到,获得积分10
43秒前
Capital发布了新的文献求助10
46秒前
48秒前
isedu完成签到,获得积分0
48秒前
AllRightReserved完成签到 ,获得积分10
49秒前
科研通AI6应助科研通管家采纳,获得150
50秒前
慕青应助科研通管家采纳,获得50
50秒前
zdyfychenyan完成签到 ,获得积分10
50秒前
科研通AI6应助科研通管家采纳,获得150
50秒前
JamesPei应助现代小丸子采纳,获得10
54秒前
mike2012完成签到 ,获得积分10
55秒前
12305014077完成签到 ,获得积分10
56秒前
小宝发布了新的文献求助10
56秒前
量子星尘发布了新的文献求助10
57秒前
包容的忆灵完成签到 ,获得积分10
57秒前
从容的水壶完成签到 ,获得积分10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
dashi完成签到 ,获得积分10
1分钟前
忧伤的慕梅完成签到 ,获得积分10
1分钟前
1分钟前
时尚丹寒完成签到 ,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Handbook of Milkfat Fractionation Technology and Application, by Kerry E. Kaylegian and Robert C. Lindsay, AOCS Press, 1995 1000
A novel angiographic index for predicting the efficacy of drug-coated balloons in small vessels 500
Textbook of Neonatal Resuscitation ® 500
The Affinity Designer Manual - Version 2: A Step-by-Step Beginner's Guide 500
Affinity Designer Essentials: A Complete Guide to Vector Art: Your Ultimate Handbook for High-Quality Vector Graphics 500
Optimisation de cristallisation en solution de deux composés organiques en vue de leur purification 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5079451
求助须知:如何正确求助?哪些是违规求助? 4297713
关于积分的说明 13388621
捐赠科研通 4120841
什么是DOI,文献DOI怎么找? 2256844
邀请新用户注册赠送积分活动 1261120
关于科研通互助平台的介绍 1195129